A novel fiber-optic acoustic sensor using an erbium-doped fiber amplifier (EDFA)-based fiber ring laser and a balanced Sagnac interferometer for acoustic sensing of the partial discharge (PD) in power transformers is proposed and demonstrated. As a technical background, an experimental investigation on how the variations of the fiber birefringence affect the sensor performances was carried out, and the results are discussed. The operation principles are described, and the relevant formulas are derived. The analytical results show that an EDFA-based fiber ring laser operating in chaotic mode can provide a degree of polarization (DOP) tunable light beam for effectively suppressing polarization fading noises. The balanced Sagnac interferometer can eliminate command intensity noises and enhance the signal-to-noise ratio (SNR). Furthermore, it inherently operates at the quadrature point of the response curve without any active stabilizations. Several experiments are conducted for evaluating the performances of the sensor system, as well as for investigating the ability of the detection of high-frequency acoustic emission signals. The experimental results demonstrate that the DOP of the laser beam can be continuously tuned from 0.2% to 100%, and the power fluctuation in the whole DOP tuning range is less than 0.05 dBm. A high-frequency response up to 300 kHz is reached, and the high sensing sensitivity for detections of weak corona discharges, as well as partial discharges also is verified.
Compared to the conventional mechanical and electrical/electronic humidity sensors, fiber-optic based humidity sensors [6,14], including silica glass fiber and polymer optical fiber (POF) based sensors [28, 46], demonstrate many unique advantages, such as small size and low weight, immunity to electromagnetic interference, corrosion resistance, potentials for remote operation and distributed sensing. In fiber-optic sensor family, the fiber grating
BackgroundPostoperative symptoms, bowel dysfunction and recurrence are common problems after resection of colorectal polyps. We aimed to evaluate the efficacy of Bifidobacterium in the postoperative patients.MethodsIn this single-center, randomized, double-blind, placebo-controlled trial, adults (≥ 18 years) undergoing endoscopic resection of colorectal polyps were treated with probiotics (Bifidobacterium animalis subsp. lactis MH-02, 2 × 109 colony-forming units per packet) or placebo once daily for 7 days. The primary clinical endpoint was a reduction in the mean total postoperative symptoms score within 7 days postoperatively. Secondary clinical endpoints were the single symptom scores, time to recovery of bowel function, and changes in the intestinal microbiota. This study is registered with the number ChiCTR2100046687.ResultsA total of 100 individuals were included (48 in probiotic group and 52 in placebo group). No difference was seen in the mean scores between the two groups (0.29 vs. 0.43, P = 0.246). Colorectal polyps size (P = 0.008) and preoperative symptoms (P = 0.032) were influential factors for the primary endpoint. Besides, MH-02 alleviated difficult defecation (P = 0.045), and reduced the time to recovery of bowel function (P = 0.032). High-throughput analysis showed that MH-02 can help restore the diversity of intestinal microbiota, and increased the relative abundance of Bifidobacterium, Roseburia, Gemmiger, Blautia and Ruminococcus, while reduced the relative abundance of Clostridium at genus level (P < 0.05).ConclusionIn this prospective trial, MH-02 showed efficacy in patients with resection of colorectal polyps, particularly in the recovery of bowel function, and the changes in the intestinal microbiota may provide evidence for further exploration of the therapeutic mechanisms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.